Tumor-infiltrating immune cells (TICs) are involved in tumor progression and determine the prognosis. We investigated how TICs affect the prognosis and therapeutic effects of squamous cell carcinoma (SCC), which share common histological features and certain risk factors. The SCC data from The Cancer Genome Atlas (TCGA) and Gene expression Omnibus (GEO) databases were downloaded to evaluate the composition of TICs with the CIBERSORT algorithm. LASSO and Cox multivariate regression analyses were used to build a prognostic risk model. Chemotherapeutic and immunotherapeutic responses were compared between patients with SCC. A Gene set variation analysis (GSVA) was also performed to elucidate the mechanism. Naïve B cells and resting mast cells were selected to construct the prognostic model. According to these two immune cell subtypes, patients with SCC were divided into low- and high-risk groups. The low-risk group with high proportions of naïve B cells and resting mast cells had a better overall survival rate than the high-risk group and might benefit from immunotherapy and chemotherapy due to differences in the immune microenvironment. Activation of the Wnt signaling pathway was observed in the high-risk group. Based on the findings from the present study, the immune signature provides prognostic determinants of SCC and may be a biomarker to guide chemotherapy and immunotherapy. Wnt inhibitors may be attractive candidates for combination treatment in high-risk patients with SCC.

肿瘤浸润免疫细胞（TICs）参与肿瘤的进展并确定预后。我们调查了TIC如何影响鳞状细胞癌（SCC）的预后和治疗效果，鳞状细胞癌具有共同的组织学特征和某些危险因素。下载了来自癌症基因组图谱（TCGA）和基因表达综合（GEO）数据库的SCC数据，以使用CIBERSORT算法评估TIC的组成。LASSO和Cox多元回归分析用于建立预后风险模型。比较了SCC患者的化学治疗和免疫治疗反应。还进行了基因组变异分析（GSVA）来阐明其机制。选择原始的B细胞和静息的肥大细胞来构建预后模型。根据这两种免疫细胞亚型，SCC患者分为低风险和高风险组。具有低水平的原始B细胞和静息肥大细胞的低风险组比高风险组具有更好的总体存活率，并且由于免疫微环境的差异，可能会受益于免疫疗法和化学疗法。在高风险组中观察到Wnt信号通路的激活。根据本研究的发现，免疫标记提供了SCC的预后决定因素，并且可能是指导化学疗法和免疫疗法的生物标记。Wnt抑制剂可能是高危SCC患者联合治疗的有吸引力的候选药物。具有低水平的初生B细胞和静息肥大细胞比例的低风险组比高风险组具有更好的总体生存率，并且由于免疫微环境的差异，可能会受益于免疫疗法和化学疗法。在高风险组中观察到Wnt信号通路的激活。根据本研究的发现，免疫标记提供了SCC的预后决定因素，并且可能是指导化学疗法和免疫疗法的生物标记。Wnt抑制剂可能是高危SCC患者联合治疗的有吸引力的候选药物。具有低水平的初生B细胞和静息肥大细胞比例的低风险组比高风险组具有更好的总体生存率，并且由于免疫微环境的差异，可能会受益于免疫疗法和化学疗法。在高风险组中观察到Wnt信号通路的激活。根据本研究的发现，免疫标记提供了SCC的预后决定因素，并且可能是指导化学疗法和免疫疗法的生物标记。Wnt抑制剂可能是SCC高危患者联合治疗的有吸引力的候选药物。免疫信号提供了SCC的预后决定因素，可能是指导化学疗法和免疫疗法的生物标志物。Wnt抑制剂可能是SCC高危患者联合治疗的有吸引力的候选药物。免疫信号提供了SCC的预后决定因素，可能是指导化学疗法和免疫疗法的生物标志物。Wnt抑制剂可能是高危SCC患者联合治疗的有吸引力的候选药物。